Scaling up human papillomavirus vaccination: a conceptual framework of vaccine adherence
Ingrid T. Katz A B H , Norma C. Ware B , Glenda Gray C , Jessica E. Haberer B D G , Claude A. Mellins F and David R. Bangsberg B D E GA Division of Women’s Health, Brigham and Women’s Hospital, Boston, MA 02120, USA.
B Harvard Medical School, Boston, MA 02115, USA.
C Perinatal HIV Research Unit, University of the Witwatersrand, PO Box 114, Diepkloof, Johannesburg, Soweto, South Africa.
D Massachusetts General Hospital Center for Global Health, Boston, MA 02114, USA.
E Ragon Institute of MGH, MIT and Harvard, Charlestown, MA 02129, USA.
F HIV Center for Clinical and Behavioral Studies, New York State Psychiatric Institute and Columbia University, New York, NY 10032, USA.
G Harvard Institute for Global Health, 104 Mt Auburn Street, 3rd Floor, Cambridge, MA 02138, USA.
H Corresponding author. Email: ikatz2@partners.org
Sexual Health 7(3) 279-286 https://doi.org/10.1071/SH09130
Submitted: 1 December 2009 Accepted: 13 April 2010 Published: 19 August 2010
Abstract
This review article provides a conceptual framework for human papillomavirus (HPV) vaccine acceptance and adherence, with a focus on improving understanding of the sociocultural factors impacting vaccine adherence behaviour. We include a systematic review of the slowly expanding literature on HPV vaccine acceptability and uptake in developed nations, as well as the relatively few publications from poorer nations, where more than 80% of global cervical cancer related deaths occur and where the vaccine will probably have the largest impact. We suggest that this conceptual framework will not only improve our understanding of HPV vaccine uptake and adherence, but it may also guide future sociobehavioural research geared towards improving adherence to the HPV vaccine and other multi-step vaccines in a young population at risk for sexually transmissible infections.
Additional keywords: adolescents, development, sexually transmissible infection.
Acknowledgements
Grant Support: Dr Katz received grant support from a KL2 Medical Research Investigator Training (MeRIT) grant awarded via Harvard Catalyst, The Harvard Clinical and Translational Science Center (NIH grant #1KL2RR025757–01, and financial contributions from Harvard University and its affiliated academic health care centres). Dr Ware received grant support from National Institute of Mental Health R21MH085557–01A1. Dr Gray received grant support from National Institute of Mental Health R21MH083308–02. Dr Haberer received grant support from National Institute of Mental Health K-23 087228 and R21 083306. Dr Mellins received support from National Institute of Mental Health R01MH069133–06A1 and 3R01MH069133–06A1S1, and National Institute of Nursing Research 5R21NR010474–02. Dr Bangsberg received grant support from National Institute of Mental Health K-24 87227, and The Mark and Lisa Schwartz Family Foundation.
[1] Muñoz N, Castellsagué X, de González AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24 1–10.
| Crossref | GoogleScholarGoogle Scholar | PubMed | [verified November 2009]
[84] Heise LL, Elias C. Transforming AIDS prevention to meet women’s needs: a focus on developing countries. Soc Sci Med 1995; 40 931–43.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[85] d’Cruz-Grote D. Prevention of HIV infection in developing countries. Lancet 1996; 348 1071–4.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
[86] Esparza J, Osmanov S, Pattou-Markovic C, Toure C, Chang ML, Nixon S. Past, present and future of HIV vaccine trials in developing countries. Vaccine 2002; 20 1897–8.
| Crossref | GoogleScholarGoogle Scholar | PubMed |
